The FDA lifted the partial clinical hold on Arcellx Inc's ACLX iMMagine-1 Phase 2 Clinical Program. The move follows alignment with FDA on modifications to the iMMagine-1 trial protocol related to ...
In today's fast-paced and ever-evolving landscape of clinical trials, the ability to efficiently analyze and visualize data has become paramount. The vast amounts of data generated from these trials ...
MI-Common Data Model: Extending Observational Medical Outcomes Partnership-Common Data Model (OMOP-CDM) for Registering Medical Imaging Metadata and Subsequent Curation Processes The Osteosarcoma ...
Abstract recently submitted in anticipation of initial data analysis ahead of ESCCompany expects to report topline LEVEL results in AugustCHAPEL ...
Two innovative, forward-thinking organizations show how rebuilding patient trust is becoming the real breakthrough driving ...
Prognostic Impact of Prostate-Specific Antigen at 6 Months After Radiotherapy in Localized Prostate Cancer: An Individual Patient Data Analysis of Randomized Trials National estimates of cancer ...
Despite rapid growth, only 9.2% of DCTs are multiregional and over 80% single-country, indicating challenges in international implementation. 2 With regulatory agencies 4–7 underscoring risk-based ...
Investors, analysts, doctors, and even patients face an avalanche of news from biotech companies about their human trials of experimental drugs, and wading through all that data to draw reasonable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results